Covid-19: Another Vaccine Proposed
- Par Dilian WELLENG
- 19 oct. 2020 17:14
- 0 Likes
The jab manufactured by a drug producing company known as Pfizer is currently under clinical trials.
Efforts to completely oust the Covid-19 pandemic are multiplying with a recent move being the manufacture of another vaccine by a world leading drug company, Pfizer, said to be able to prevent the deadly coronavirus. Pfizer is reported to have already manufactured 'several hundred thousand doses' of the jab at its plant in Puurs, Belgium. The vaccine has been hoarded for clinical trails and will only be distributed worldwide if the trials are a success, and regulators deem it safe and effective, sources have confirmed. Reports further indicate that the US giant hopes to make 100 million doses available this year, of which 40 million are destined for the UK. If the vaccine is confirmed, sources say, every patient who receives the vaccine will need two doses. Talking with an international media outlet, yesterday, Pfizer UK boss Ben Osborn says: “It was great to see the first vial coming off the manufacturing line.” “It just brought a tremendous smile to my face to see all of this work actually result in a product,” he adds.
This recent development comes to add to several other proposals which on several occasions sparked controversies. On August 11, 2020, Russia became the first country in the world to approve a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine, which is based on two adenovirus vectors, was developed by the Gamaleya National Center of Epidemiology and Microbiology (Moscow, Russia). Its approval was announced by President Vladimir Putin. After some time, the va...
Cet article complet est réservé aux abonnés
Déjà abonné ? Identifiez-vous >
Accédez en illimité à Cameroon Tribune Digital à partir de 26250 FCFA
Je M'abonne1 minute suffit pour vous abonner à Cameroon Tribune Digital !
- Votre numéro spécial cameroon-tribune en version numérique
- Des encarts
- Des appels d'offres exclusives
- D'avant-première (accès 24h avant la publication)
- Des éditions consultables sur tous supports (smartphone, tablettes, PC)
Commentaires